Trial Profile
Mesothelioma Stratified Therapy (MiST): A Stratified Multi-arm Phase IIa Clinical Trial to Enable Accelerated Evaluation of Targeted Therapies for Relapsed Malignant Mesothelioma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Oct 2023
Price :
$35
*
At a glance
- Drugs Abemaciclib (Primary) ; Atezolizumab (Primary) ; Bemcentinib (Primary) ; Bevacizumab (Primary) ; Dostarlimab (Primary) ; Niraparib (Primary) ; Pembrolizumab (Primary) ; Rucaparib (Primary)
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- Acronyms MiST; MIST3
- 06 Jun 2023 Results assessing knowledge gap through multi-omic interrogation of tumours from patients enrolled into arm 4 of this trial, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 06 Jun 2023 Results (n=26) assessing cellular and molecular correlates of efficacy in patients with relapsed mesothelioma presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 25 May 2023 According to a BerGenBio media release, an abstract of oral presentation including the results from this study accepted for the presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago June 2-6, 2023.